Medical journal of the Islamic Republic of Iran
-
Med J Islam Repub Iran · Jan 2020
Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection.
Background: Coronavirus disease 2019 (COVID-19) is caused by a new severe acute respiratory syndrome Coronavirus. COVID-19 patients are at risk for acute respiratory distress syndrome and death from respiratory failure. Methods: In this study the complete genome of the SARS-CoV-2 reference sequence, geologically isolated types, and Coronavirus related to human diseases were compared by the Molecular Phylogenetic Maximum Likelihood method. ⋯ Furthermore, implementing recombinant human ACE2 as a competitive receptor might be an effective way to trap and chelate the SARS-CoV-2 particles. Conclusion: The data suggest that combination therapy of angiotensin II receptor blockers and C21 could be a potential pharmacologic regimen to control and reduce acute respiratory distress syndrome. Moreover, rhACE2 can be recommended as an effective protective antiviral therapy in the treatment of COVID-19 and its complications.
-
Med J Islam Repub Iran · Jan 2020
Modeling and forecasting trend of COVID-19 epidemic in Iran until May 13, 2020.
Background: COVID-19 is a new disease and precise data are not available about this illness in Iran and in the world. Thus, this study aimed to determine the epidemic trend and prediction of COVID-19 in Iran. Methods: This was a secondary data analysis and modeling study. ⋯ Based on Gompertz and von models, 7900 (6200- 9300) and 4620 (3930- 5550) deaths will occur from May 13 to June 1, 2020, respectively, and then the curve will flatten. Conclusion: In this study, estimations were made based on severely ill patients who were in need of hospitalization. If enforcement and public behavior interventions continue with current trends, the COVID-19 epidemic will be flat from May 13 until July, 2020 in Iran.
-
Med J Islam Repub Iran · Jan 2020
Can judgments according to case fatality rate be correct all the time during epidemics? Estimated cases based on CFR in different scenarios and some lessons from early case fatality rate of coronavirus disease 2019 in Iran.
Background: The new Coronavirus disease (COVID-19) was first identified in China in 2019. Case fatality rate (CFR) indicator of the disease is one of the most important indices noticed by experts, policymakers, and managers, based on which daily evaluations and many judgments are made. CFR can change during epidemics. ⋯ Moreover, it is suggested that in the outbreak of an epidemic, specifically emerging diseases, CFR must not be the base of judgment. Making judgments, specifically in the outbreak of emerging epidemics, based on fatality rate can lead to information bias. It is also possible to estimate the total number of patients based on the CFR in circumstances where little information is available on the disease.